ARHGEF18 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q6ZSZ5 |
Other Accession | NP_056133.2 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 151642 Da |
Antigen Region | 91-119 aa |
Gene ID | 23370 |
---|---|
Other Names | Rho guanine nucleotide exchange factor 18, 114 kDa Rho-specific guanine nucleotide exchange factor, p114-Rho-GEF, p114RhoGEF, Septin-associated RhoGEF, SA-RhoGEF, ARHGEF18, KIAA0521 |
Target/Specificity | This ARHGEF18 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 91-119 amino acids from the N-terminal region of human ARHGEF18. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | ARHGEF18 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | ARHGEF18 |
---|---|
Synonyms | KIAA0521 |
Function | Acts as a guanine nucleotide exchange factor (GEF) for RhoA GTPases. Its activation induces formation of actin stress fibers. Also acts as a GEF for RAC1, inducing production of reactive oxygen species (ROS). Does not act as a GEF for CDC42. The G protein beta-gamma (Gbetagamma) subunits of heterotrimeric G proteins act as activators, explaining the integrated effects of LPA and other G-protein coupled receptor agonists on actin stress fiber formation, cell shape change and ROS production. Required for EPB41L4B-mediated regulation of the circumferential actomyosin belt in epithelial cells (PubMed:22006950). |
Cellular Location | Cytoplasm. Cytoplasm, cytoskeleton. Cell membrane. Apical cell membrane. Note=In unactivated eosinophils, distributed around the cell periphery in the perimembranous region (PubMed:29601110). In activated eosinophils, relocates to the tip of the nucleopod, a membrane structure formed during activation when the nucleus moves to one end of the cell, and is also concentrated in membrane protrusions at the opposite end of the cell (PubMed:29601110) Localizes to the apical cell membrane in epithelial cells (PubMed:22006950). |
Tissue Location | Expressed in all tissues tested with highest expression in kidney and pancreas. Weakly or not expressed in liver, skeletal muscle and testis. Isoform 1: Expressed in eosinophils (PubMed:29601110). Isoform 2: Expressed in eosinophils (PubMed:29601110). Isoform 3: Expressed in eosinophils (PubMed:29601110). Isoform 4: Not detected in eosinophils (PubMed:29601110). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Rho GTPases are GTP binding proteins that regulate a wide spectrum of cellular functions. These cellular processes include cytoskeletal rearrangements, gene transcription, cell growth and motility. Activation of Rho GTPases is under the direct control of guanine nucleotide exchange factors (GEFs). The protein encoded by this gene is a guanine nucleotide exchange factor and belongs to the Rho GTPase GFE family. Family members share a common feature, a Dbl (DH) homology domain followed by a pleckstrin (PH) homology domain. Alternatively spliced transcript variants encoding different isoforms have been identified.
References
Ichikawa, S., et al. J. Bone Miner. Res. 25(8):1821-1829(2010)
Niu, J., et al. Circ. Res. 93(9):848-856(2003)
Rabizadeh, S., et al. Cytokine Growth Factor Rev. 14 (3-4), 225-239 (2003) :
Salehi, A.H., et al. J. Biol. Chem. 277(50):48043-48050(2002)
Harrington, A.W., et al. J. Neurosci. 22(1):156-166(2002)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.